Cell-Based Cancer Therapy Prodded by Custom IL-2 Keeps Going and Going

Whether you spare the rod or wield it freely, you risk spoiling the cell-based cancer therapy. The rod in this case is interleukin-2 (IL-2), a signaling chemical that awakens T cells to their cancer-fighting duties. Letting up on the IL-2 allows T cells to err on the side of sloth. Persistent administration, however, raises the risks of serious side effects.To circumvent this dilemma, scientists based at Stanford University School of Medicine worked out a unique approach. They would brandish a m